{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:24:50Z","timestamp":1790076290479,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the more recently investigated adverse long\u2010term side effects of gonadotropin\u2010releasing hormone (Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content>) agonists for prostate cancer (<jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>a) is cardiovascular disease (<jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content>). Studies suggest lower risk of <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> following Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> antagonists (degarelix) than Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> following Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> agonists and antagonists for <jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>a.<\/jats:p><jats:p><jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>a men on primary Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> agonists or antagonists were identified from the <jats:styled-content style=\"fixed-case\">UK THIN<\/jats:styled-content> (The Health Improvement Network) database, National Health Service (<jats:styled-content style=\"fixed-case\">NHS<\/jats:styled-content>) Scotland, Belgian Cancer Registry (<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>), Dutch <jats:styled-content style=\"fixed-case\">PHARMO<\/jats:styled-content> Database Network and French National Database (<jats:styled-content style=\"fixed-case\">SNIIRAM<\/jats:styled-content>). Cohort entry was defined as date of treatment initiation. <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> event was defined as any first incident or fatal <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> after cohort entry. Readcodes in <jats:styled-content style=\"fixed-case\">THIN<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content> codes in <jats:styled-content style=\"fixed-case\">NHS<\/jats:styled-content> Scotland, <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PHARMO<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">SNIIRAM<\/jats:styled-content> were used to extract variables. Risk of Bias in Non\u2010randomised studies of Interventions (<jats:styled-content style=\"fixed-case\">ROBINS<\/jats:styled-content>\u2010I) tool was used to assess the potential risk of biases in this study. 51 572 men with a median follow\u2010up time of 2 years started on Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> agonists and 2 417 men with a median follow\u2010up time of 1 year started on Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> antagonists between 2010 and 2017 in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>, Scotland, Belgium, the Netherlands and France. Data from five countries improved the study power and internal validity required to compare risk of <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> between Gn<jats:styled-content style=\"fixed-case\">RH<\/jats:styled-content> agonists and antagonists, the latter being a fairly new drug with limited data in individual countries.<\/jats:p>","DOI":"10.1111\/fcp.12454","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T16:16:34Z","timestamp":1550506594000},"page":"479-499","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world insights into risk of developing cardiovascular disease following Gn<scp>RH<\/scp> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-5507","authenticated-orcid":false,"given":"Gincy","family":"George","sequence":"first","affiliation":[{"name":"Translational Oncology and Urology Research King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-9107","authenticated-orcid":false,"given":"Lucie\u2010Marie","family":"Scailteux","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Center Rennes Hospital University Rennes France"},{"name":"REPERES (Pharmacoepidemiology and Heath Services Research) Rennes University EA 7449, F\u201035000 Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[{"name":"Translational Oncology and Urology Research King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Balusson","sequence":"additional","affiliation":[{"name":"REPERES (Pharmacoepidemiology and Heath Services Research) Rennes University EA 7449, F\u201035000 Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cardwell","sequence":"additional","affiliation":[{"name":"Centre for Public Health Institute for Health Sciences Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet De","family":"Coster","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlinde De","family":"Schutter","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephina G.","family":"Kuiper","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dana","family":"McMenamin","sequence":"additional","affiliation":[{"name":"Centre for Public Health Institute for Health Sciences Queen's University Belfast Belfast Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Verbeeck","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[{"name":"Translational Oncology and Urology Research King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051415816674103"},{"issue":"1","key":"e_1_2_7_4_1","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter M.A.","year":"2007","journal-title":"Rev. Urol."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-3-259"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9741"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2497"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.06051.x"},{"key":"e_1_2_7_9_1","first-page":"518","volume-title":"Prostate cancer: principles and practice","author":"Petrylak P.J.","year":"2002"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22933"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200505030-00001"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3369"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm168"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1792"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1567"},{"key":"e_1_2_7_16_1","first-page":"7847","article-title":"Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20\u201324, 2015, Madrid, Spain","volume":"22","author":"Barkin J.","year":"2015","journal-title":"Can. J. Urol."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.032"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.06.018"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1818-2"},{"key":"e_1_2_7_20_1","unstructured":"ClinicalTrials.gov.A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE). (2018) Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02663908(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780020222"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422506"},{"key":"e_1_2_7_24_1","unstructured":"GeorgeG. ScailteuxL.M. GarmoH.et al.The risk of cardiovascular disease following GnRH agonists versus antagonists: real\u2010world evidence from four European countries. Poster presented at: Expert\u2010guided Poster Presentation. 33rd Annual European Association of Urology Congress Copenhagen Denmark (2018a) pp.16\u201320."},{"key":"e_1_2_7_25_1","unstructured":"GeorgeG. ScailteuxL.M. GarmoH.et al.Real\u2010world insights into risk of cardiovascular disease following GnRH agonists and antagonists in men with prostate cancer. Poster presented at: Poster Reception. Global Cardio\u2010Oncology Summit 2018 Florida United States of America (2018b) 27th \u2010 28th September."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_7_27_1","unstructured":"LodwickR.K.THIN database. (2015) Available from:https:\/\/www.ucl.ac.uk\/pcph\/research-groups-themes\/thin-pub\/database(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_28_1","unstructured":"IMS Health Incorporated.Data content. (2015) Available from:http:\/\/csdmruk.cegedim.com\/our-data\/data-content.shtml(Accessed date: 10\/10\/2017)."},{"key":"e_1_2_7_29_1","unstructured":"Vision Health.Vision Health. (2017) Available from:https:\/\/www.visionhealth.co.uk\/(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2532.1994.1130177.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw060"},{"key":"e_1_2_7_32_1","unstructured":"Belgian Cancer Registry.Belgian Cancer Registry. (2017) Available from:http:\/\/www.kankerregister.org\/Belgian%20Cancer%20Registry(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_33_1","unstructured":"Belgian Law:Deliberation No. 09\/071 of 15 September 2009 last amended on 18 February 2014 relating to the communication of personal data by insurers to the Cancer Registry Foundation under Article 45 quinquies of the Royal Decree number 78 of 10 November 1967 concerning the practice of health care professions."},{"key":"e_1_2_7_34_1","unstructured":"Belgian Law:Deliberation No. 16\/021 of 15 March 2016 on the communication of coded personal health data by the technical unit to the Cancer Registry Foundation for the assessment of comorbidity in cancer patients in the context of scientific research projects."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.09.010"},{"key":"e_1_2_7_36_1","unstructured":"PHARMO Institute.PHARMO Database Network. (2017) Available from:http:\/\/pharmo.nl\/what-we-have\/pharmo-database-network\/(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_37_1","unstructured":"Ameli.SNIIRAM. (2016) Available from:https:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/sniiram\/finalites-du-sniiram.php(Accessed date: 05\/04\/2018)."},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_7_39_1","first-page":"221","volume-title":"Inequality and the North","author":"Mackenbach J.P.","year":"1987"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.725"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_2_7_42_1","first-page":"105","volume-title":"Understanding pharmacoepidemiology","author":"Said Q.","year":"2010"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.11"},{"key":"e_1_2_7_44_1","unstructured":"National Institute for Health and Care Excellence.Degarelix for treating advanced hormone\u2010dependent prostate cancer. Final Scope. (2013) Available from:https:\/\/www.nice.org.uk\/guidance\/ta404\/documents\/prostate-cancer-advanced-hormone-dependent-degarelix-depot-final-scope2(Accessed date: 21\/02\/2018)."},{"key":"e_1_2_7_45_1","unstructured":"National Institute for Health and Care Excellence.Prostate Cancer: diagnosis and treatment. (2014) Available from:https:\/\/www.nice.org.uk\/guidance\/cg175\/evidence\/full-guideline-191710765(Accessed date: 21\/02\/2018)."},{"key":"e_1_2_7_46_1","unstructured":"National Institute for Health and Care Excellence.Final Appraisal Determination: Degarelix for treating advanced hormone\u2010dependent prostate cancer. (2014) Available from:https:\/\/www.nice.org.uk\/guidance\/ta404\/documents\/prostate-cancer-advanced-hormone-dependent-degarelix-depot-fad-document2(Accessed date: 06\/04\/2018)."},{"key":"e_1_2_7_47_1","unstructured":"Royal Decree of 31\/12\/2001 \u2013 IV \u2013 2360000 \u2013 Law on various health provisions of December 13 2006 article 39. Moniteur Belge (2006)."},{"key":"e_1_2_7_48_1","unstructured":"Haute Autorit\u00e9 De Sant\u00e9.Transparency committee opinion Firmagon. (2009) Available from:https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2011-02\/firmagon_ct_6725.pdf(Accessed date: 06\/04\/2018)."},{"key":"e_1_2_7_49_1","unstructured":"De BoerJ.E.CFH\u2010rapport 09\/19: degarelix (Firmagon\u00ae). (2009) Available from:https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/rapport\/2009\/07\/27\/degarelix-firmagon-bij-hormoonafhan0kelijke-prostaatkanker-in-een-vergevorderd-stadium\/Degarelix+(Firmagon)+bij+hormoonafhankelijke+prostaatkanker+in+een+vergevorderd+stadium.pdf(Accessed date: 06\/04\/2018)."},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn135"},{"key":"e_1_2_7_51_1","unstructured":"INAMI\u2010RIZIV.Nomenclature: research criteria. (2018) Available from:http:\/\/ondpanon.riziv.fgov.be\/nomen\/fr\/search(Accessed date: 06\/04\/2018)."}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:23:25Z","timestamp":1694294605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/fcp.12454"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12454","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"2018-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}